WO2023073013 - LRRK2 INHIBITORS
National phase entry:
Publication Number
WO/2023/073013
Publication Date
04.05.2023
International Application No.
PCT/EP2022/079927
International Filing Date
26.10.2022
Title **
[English]
LRRK2 INHIBITORS
[French]
INHIBITEURS DE LRRK2
Applicants **
H. LUNDBECK A/S
Ottiliavej 9
2500 Valby, DK
Inventors
JENSEN, Thomas
c/o H. Lundbeck A/S
Ottiliavej 9
2500 Valby, DK
JESSING, Mikkel
c/o H. Lundbeck A/S
Ottiliavej 9
2500 Valby, DK
YU, Wanwan
c/o H. Lundbeck A/S
Ottiliavej 9
2500 Valby, DK
DIAZ, David Rodriguez
c/o H. Lundbeck A/S
Ottiliavej 9
2500 Valby, DK
NIELSEN, Jacob
c/o H. Lundbeck A/S
Ottiliavej 9
2500 Valby, DK
JONES, Christopher Richard
c/o H. Lundbeck A/S
Ottiliavej 9
2500 Valby, DK
ANDERSEN, Thomas
c/o H. Lundbeck A/S
Ottiliavej 9
2500 Valby, DK
JACOBSEN, Mikkel Fog
c/o H. Lundbeck A/S
Ottiliavej 9
2500 Valby, DK
Priority Data
21204970.4
27.10.2021
EP
22201380.7
13.10.2022
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2939 | |
| EPO | Filing, Examination | 11772 | |
| Japan | Filing | 594 | |
| South Korea | Filing | 608 | |
| USA | Filing, Examination | 6060 |
Total: 21973 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention is directed to compounds of formula I. The compounds are considered useful for the treatment of diseases associated with LRRK2 such as Parkinson's disease.[French]
La présente invention concerne des composés de formule I. Les composés sont considérés utiles pour le traitement de maladies associées à LRRK2 telles que la maladie de Parkinson.